Table 1.
Characteristics of patient with sarcoidosis in the current study
| Mean or proportion (N = 89) | |
| Age at diagnosis in years (standard deviation) | 46.8 (13.9) |
| Duration of follow-up (standard deviation) | 5.4 (4.5) |
| Male | 17 (19.1%) |
| Intrathoracic disease | |
| Intrathoracic involvement -Stage I -Stage II -Stage III -Stage IV |
81 (91.0%) 43 (53.1%) 32 (39.5%) 5 (6.2%) 1 (1.2%) |
| Pulmonary symptoms -Dyspnea -Cough -Chest pain |
34 (41.9%) 21 (25.9%) 18 (22.2%) 2 (2.5%) |
| Extrathoracic disease | |
| Uveitis | 35 (39.3%) |
| Skin | 24 (26.9%) |
| Joint | 4 (4.5%) |
| Nervous system | 3 (3.4%) |
| Kidney | 3 (3.4%) |
| Parotid gland | 3 (3.4%) |
| Liver | 2 (2.2%) |
| Spleen | 2 (2.2%) |
| Heart | 2 (2.2%) |
| Bone | 1 (1.1%) |
| Extrathoracic lymph node | 18 (22.5%) |
| Hypercalcemia | 9 out of 56 patients who had at least one calcium level checked (16.1%) |
| Biopsy (positive for non-caseous granuloma / number performed) | |
| Intrathoracic | 53/68 (77.9%)* |
| Skin | 21/22 (95.5%) |
| Extrathoracic lymph node | 8/8 (100.0%) |
| Parotid gland | 1/1 (100.0%) |
| Kidney | 1/1 (100.0%) |
| Treatment | |
| Oral prednisolone | 46 (51.7%) |
| Methotrexate | 16 (17.9%) |
| Azathioprine | 8 (9.0%) |
| Chloroquine | 3 (3.4%) |
| Leflunomide | 1 (1.1%) |
| Sulfasalazine | 1 (1.1%) |
| Inhaled corticosteroids | 6 (6.7%) |
| Topical corticosteroids | 28 (31.5%) |
*One case was positive for caseous granuloma